Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

The Hospital Anxiety and Depression Scale

Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · see citing works

Untitled work

(1992) · PubMed · Cited by 33,716 · see citing works

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works

The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · see citing works

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)

Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works

The metabolic syndrome—a new worldwide definition

Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · see citing works

A sharper Bonferroni procedure for multiple tests of significance

HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829 · see citing works

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism

Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165 · see citing works

Mechanisms linking obesity with cardiovascular disease

Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · see citing works

In the Netherlands

van Gelder, H. A. E. (1961) · Springer eBooks · doi:10.1007/978-94-011-9562-1_10 · Cited by 1,657 · see citing works

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,500 · see citing works

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients

Pi-Sunyer, X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & for the RIO-North America Study Group (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,209 · see citing works

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

Cota, D., Marsicano, G., Tschöp, M. H., Grübler, Y., Flachskamm, C., Schubert, M. I., Auer, D. P., Yassouridis, A., Thöne‐Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168 · see citing works

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

Osei‐Hyiaman, D., DePetrillo, M. A., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J. D., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23057 · Cited by 1,103 · see citing works

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · see citing works

Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation

Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934 · see citing works

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)

Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872 · see citing works

Endocannabinoid control of food intake and energy balance

Marzo, V. D., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 746 · see citing works

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

Scheen, A. J., Finer, N., Hollander, P. A., Jensen, M. D., & Gaal, L. F. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 729 · see citing works

Activation of the peripheral endocannabinoid system in human obesity

Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686 · cited 1× · see citing works

Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β-Pancreatic Cells and in Obesity and Hyperglycemia

Matias, I., Gonthier, M., Orlando, P., Martiadis, V., PETROCELLIS, L. D., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 654 · see citing works

The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells

Bensaïd, M., Gary‐Bobo, M., Esclangon, A., Maffrand, J., Fur, G. L., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593 · see citing works

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

Ravinet‐Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 563 · see citing works

The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance

Jbilo, O., Ravinet‐Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Fur, G. L., Galiègue, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3177fje · Cited by 346 · see citing works

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice

Liu, Y., Connoley, I. P., WILSON, C. A., & Stock, M. J. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802847 · Cited by 314 · see citing works

Untitled work

(1997) · PubMed · Cited by 302 · see citing works

Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)

Sipe, J. C., Waalen, J., Gerber, A., & Beutler, E. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802954 · Cited by 257 · see citing works

Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell

Juan-Picó, P., Fuentes, E., Bermúdez-Silva, F., Díaz-Molina, F. J., Ripoll, C., de Fonseca, F. D., & Nadal, A. (2006) · Cell Calcium · doi:10.1016/j.ceca.2005.10.005 · Cited by 251 · see citing works

Primary prevention of eating disorders: Might it do more harm than good?

Carter, J. C., Stewart, D. A., Dunn, V. J., & Fairburn, C. G. (1997) · International Journal of Eating Disorders · doi:10.1002/(sici)1098-108x(199709)22:2 · Cited by 199 · see citing works

The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract

Massa, F., Storr, M., & Lutz, B. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0698-5 · Cited by 142 · see citing works

Laboratory Test Handbook

Jacobs, D. S. (1990) · Cited by 128 · see citing works

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

DEEDWANIA, P. C., & Fonseca, V. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.018 · Cited by 105 · see citing works

Weight-loss maintenance in overweight individuals one to five years following successful completion of a commercial weight loss program

Lowe, M., Miller‐Kovach, K., & Phelan, S. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801521 · Cited by 105 · see citing works

Construct Validity of the Impact of Weight on Quality of Life Questionnaire

Kolotkin, R. L., Head, S. B., & Brookhart, A. M. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00667.x · Cited by 104 · see citing works

Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis

Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870 · see citing works

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436 · see citing works

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works

Pathophysiology of NASH: perspectives for a targeted treatment

Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163 · see citing works

The CB₁Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability

Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74 · see citing works

Long-term effects of weight-reducing drugs in people with hypertension

Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70 · see citing works

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen, A. J. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01681.x · Cited by 68 · see citing works

Psychosocial and pharmacological interventions for the treatment of cannabis use disorder

Sabioni, P., & Le Foll, B. (2018) · F1000Research · doi:10.12688/f1000research.11191.1 · Cited by 37 · see citing works

Determining the optimal cutoff points for waist circumference and body mass index for identification of metabolic abnormalities and metabolic syndrome in urban Thai population

Worachartcheewan, A., Dansethakul, P., Nantasenamat, C., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.018 · Cited by 12 · see citing works

The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets

Getty‐Kaushik, L., Richard, A.-M. T., Deeney, J. T., Krawczyk, S. A., Shirihai, O. S., & Corkey, B. E. (2009) · Obesity · doi:10.1038/oby.2009.234 · Cited by 50 · see citing works

Identifying adolescent metabolic syndrome using body mass index and waist circumference.

Camhi, S. M., Kuo, J., & Young, D. R. (2008) · PubMed · Cited by 38 · see citing works

Rimonabant in obese patients with type 2 diabetes

Roberfroid, D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60261-x · Cited by 4 · see citing works

Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant

Rubio, M. Á., Gargallo, M., Millán, A. I. J., & Moreno, B. (2007) · Public Health Nutrition · doi:10.1017/s1368980007000717 · Cited by 52 · see citing works